Shares surged 141% to $6.41, marking their highest level since February 2024, after Minerva secured up to $200 million in financing led by top healthcare investors.
Minerva Neurosciences Inc (NASDAQ:NERV) shares are climbing Tuesday after the company announced up to $200 million in funding to support development of roluperidone for schizophrenia.
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday. The Dow traded down 0.35% to 38,932.26 while the NASDAQ rose 0.28% to 16,021.41. The S&P 500 also rose, gaining, 0.04% to 5,071.40.
Minerva Neurosciences faces FDA challenges for roluperidone in schizophrenia treatment. Understand the clinical deficiencies and potential paths forward. Cash position at December 31, 2023, around $41.0 million.
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Tuesday. The Dow traded down 0.39% to 38,915.65 while the NASDAQ rose 0.15% to 15,999.50. The S&P 500 also fell, dropping, 0.03% to 5,067.80.
U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 50 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.07% to 39,043.13 while the NASDAQ rose 0.31% to 16,026.43. The S&P 500 also rose, gaining, 0.10% to 5,074.75.
